HR and neoplasm: The molecular subtype of metastatic lesions in three patients was inconsistent with either side of the primary lesions, in which two patients presented with TNBC, although the primary lesions on both sides were HR+/HER2−, and one patient presented with an HR‐negative (HR−)/HER2+ tumor, but the primary lesions were HR+/HER2+ and HR+/HER2 unknown.